Efficacy and Safety of Naproxcinod in Patients with Osteoarthritis of the Knee: A 53-Week Prospective Randomized Multicenter Study

Seminars in Arthritis and Rheumatism

Volumn 40, Issue 4, 2011, Pages 285-297

  Schnitzer, Thomas J ^a   Hochberg, Marc C ^b   Marrero, Christopher E ^c   Duquesroix, Brigitte ^d   Frayssinet, Hayet ^d   Beekman, Maarten ^d  

^a NORTHWESTERN UNIVERSITY   (United States)

^b UNIVERSITY OF MARYLAND SCHOOL OF MEDICINE   (United States)

^c LOUISIANA STATE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^d NicOx SA   (France)

Author keywords

CINOD; Cyclooxygenase inhibiting nitric oxide donator; Naproxcinod; Naproxen; Osteoarthritis

Indexed keywords

ACETYLSALICYLIC ACID; NAPROXCINOD; NAPROXEN; PLACEBO;

ADULT; AGED; ANALYTICAL ERROR; ARTICLE; ASPHYXIA; CARDIOTOXICITY; CORONARY ARTERY ATHEROSCLEROSIS; DIARRHEA; DIZZINESS; DOUBLE BLIND PROCEDURE; DRUG DOSE COMPARISON; DRUG EFFICACY; DRUG FATALITY; DRUG INDUCED HEADACHE; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; FEMALE; GASTROINTESTINAL HEMORRHAGE; GASTROINTESTINAL TOXICITY; HUMAN; INFECTION; INFESTATION; KNEE OSTEOARTHRITIS; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; NAUSEA; ORTHOSTATIC HYPOTENSION; PAIN ASSESSMENT; PARALLEL DESIGN; PERIPHERAL EDEMA; PRIORITY JOURNAL; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL; SIDE EFFECT; SYSTOLIC BLOOD PRESSURE; UPPER RESPIRATORY TRACT INFECTION; URINARY TRACT INFECTION;

ADULT; AGED; AGED, 80 AND OVER; ANALYSIS OF VARIANCE; DOUBLE-BLIND METHOD; FEMALE; HUMANS; MALE; MIDDLE AGED; NAPROXEN; NITRIC OXIDE DONORS; OSTEOARTHRITIS, KNEE; PAIN; PAIN MEASUREMENT; PROSPECTIVE STUDIES; TREATMENT OUTCOME;

EID: 78751706374     PISSN: 00490172     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.semarthrit.2010.06.002     Document Type: Article

References (31)

1. Andrianakos A.A., Kontelis L.K., Karamitsos D.G., Aslanidis S.I., Georgountzos A.I., Kaziolas G.O., et al. ESORDIG Study. Prevalence of symptomatic knee, hand, and hip osteoarthritis in Greece. J Rheumatol 2006, 33(12):2507-2513.
2. Grotle M., Hagen K.B., Natvig B., Dahl F.A., Kvien T.K. Prevalence and burden of osteoarthritis: results from a population survey in Norway. J Rheumatol 2008, 35(4):677-684. [Epub 2008 Feb 15].
3. Lawrence R.C., Felson D.T., Helmick C.G., Arnold L.M., Choi H., Deyo R.A., et al. Estimates of the prevalence of arthritis and other rheumatic conditions in the United States. Part II. Arthritis Rheum 2008, 58(1):26-35.
4. Elders M.J. The increasing impact of arthritis on public health. J Rheumatol Suppl 2000, 60:6-8.
5. Van Dijk G.M., Veenhof C., Schellevis F., Hulsmans H., Bakker J.P., Arwert H., et al. Comorbidity, limitations in activities and pain in patients with osteoarthritis of the hip or knee. BMC Musculoskelet Disord 2008, 9:95.
6. Cimmino M.A., Sarzi-Puttini P., Scarpa R., Caporali R., Parazzini F., Zaninelli A., et al. Clinical presentation of osteoarthritis in general practice: determinants of pain in Italian patients in the AMICA study. Semin Arthritis Rheum 2005, 35(1 Suppl 1):17-23.
7. Kadam U.T., Jordan K., Croft P.R. Clinical comorbidity in patients with osteoarthritis: a case-control study of general practice consulters in England and Wales. Ann Rheum Dis 2004, 63(4):408-414.
8. Wallace J.L. Nonsteroidal anti-inflammatory drugs and gastroenteropathy: the second hundred years. Gastroenterology 1997, 112(3):1000-1016.
9. Shanbhag V.R., Crider A.M., Gokhale R., Harpalani A., Dick R.M. Ester and amide prodrugs of ibuprofen and naproxen: synthesis, anti-inflammatory activity, and gastrointestinal toxicity. J Pharm Sci 1992, 81(2):149-154.
10. Bing R. Why do cyclo-oxygenase-2 inhibitors cause cardiovascular events?. J Am Coll Cardiology 2002, 39(3):521-522.
11. Pope J.E., Anderson J.J., Felson D.T. A meta-analysis of the effects of nonsteroidal anti-inflammatory drugs on blood pressure. Arch Intern Med 1993, 153(4):477-484.
12. Chrischilles E.A., Wallace R.B. Nonsteroidal anti-inflammatory drugs and blood pressure in an elderly population. J Gerontol 1993, 48:M91-M96.
13. Johnson A.G., Simons L.A., Simons J., Friedlander Y., McCallum J. Non-steroidal anti-inflammatory drugs and hypertension in the elderly: a community-based cross-sectional study. Br J Clin Pharmacol 1993, 35(5):455-459.
14. Johnson A.G., Nguyen T.V., Day R.O. Do nonsteroidal anti-inflammatory drugs affect blood pressure?. A meta-analysis. Ann Intern Med 1994, 121:289-300.
15. Johnson A.G. NSAIDs and blood pressure. Clinical importance for older patients. Drugs Aging 1998, 12:17-27.
16. Armstrong E.P., Malone D.C. The impact of nonsteroidal anti-inflammatory drugs on blood pressure, with an emphasis on newer agents. Clin Ther 2003, 25:1-18.
17. Grover S.A., Coupal L., Zowall H. Treating osteoarthritis with cyclooxygenase-2-specific inhibitors: what are the benefits of avoiding blood pressure destabilization?. Hypertension 2005, 45:92-97.
18. Del Soldato P., Sorrentino R., Pinto A. NO-aspirins: a class of new anti-inflammatory and antithrombotic agents. Trends Pharmacol Sci 1999, 20:319-323.
19. Whittle B.J., Lopez-Belmonte J. Actions and interactions of endothelins, prostacyclin and nitric oxide in the gastric mucosa. J Physiol Pharmacol 1993, 44:91-107.
20. Altman R., Asch E., Bloch D., Bole D., Borenstein K., Brandt K., et al. Development of criteria for the classification and reporting of osteoarthritis. Classification of osteoarthritis of the knee. Arthritis Rheum 1986, 29:1039-1049.
21. Hochberg M.C., Chang R.W., Dwosh I., Lindsey S., Pincus T., Wolfe F. The American College of Rheumatology 1991 revised criteria for the classification of global functional status in rheumatoid arthritis. Arthritis Rheum 1992, 35:498-502.
22. Kellgren J.H., Lawrence J.S. Radiological assessment of osteoarthrosis. Ann Rheum Dis 1957, 16:494-502.
23. Dougados M., Leclaire P., van der Heijde D., Bloch D.A., Bellamy N., Altman R.D. Response criteria for clinical trials on osteoarthritis of the knee and hip: a report of the Osteoarthritis Research Society International Standing Committee for Clinical Trials response criteria initiative. Osteoarthritis Cartilage 2000, 8(6):395-403.
24. Pham T., van der Heijde D., Altman R.D., Anderson J.J., Bellamy N., Hochberg M., et al. OMERACT-OARSI initiative: Osteoarthritis Research Society International set of responder criteria for osteoarthritis clinical trials revisited. Osteoarthritis Cartilage 2004, 12(5):389-399.
25. Le Graverand M.P., Mazzuca S., Lassere M., Guermazi A., Pickering E., et al. Assessment of the radioanatomic positioning of the osteoarthritic knee in serial radiographs: comparison of three acquisition techniques. Osteoarthritis Cartilage 2006, 14(Suppl A):A37-A43. Radiography Working Group of the OARSI-OMERACT Imaging Workshop.
26. Pickering T.G., Alpert B., McCrindle B., Daniels S., Dennison B., Hayman L., et al. Recommendations for blood pressure measurement in humans and experimental animals. Part 1: Blood pressure measurements in humans. Hypertension 2005, 45:142-161. A statement for professionals from the subcommittee of Professional and Public Education of the American Heart Association Council on High Blood Pressure research.
27. Chobanian A.V., Bakris G.L., Black H.R., Cushman W.C., Green L.A., Izzo J.L., et al. Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation and Treatment of High Blood Pressure. Hypertension 2003, 42:1206-1252. National Heart, Lung, and Blood Institute; National High Blood Pressure Education Program Coordinating Committee.
28. Wilder-Smith C.H., Jonzon B., Fornstedt-Wallin B., Hedman A., Karlsson P. Dose-effect comparisons of the CINOD AZD3582 and naproxen on upper gastrointestinal tract mucosal injury in healthy subjects. Scand J Gastroenterol 2006, 41(3):264-273.
29. Lohmander L.S., McKeith D., Svensson O., Malmenäs M., Bolin L., Kalla A., et al. A randomised, placebo controlled, comparative trial of the gastrointestinal safety and efficacy of AZD3582 versus naproxen in osteoarthritis. Ann Rheum Dis 2005, 64(3):449-456.
30. Hawkey C.J., Jones J.I., Atherton C.T., Skelly M.M., Bebb J.R., Fagerholm U., et al. Gastrointestinal safety of AZD3582, a cyclooxygenase inhibiting nitric oxide donator: proof of concept study in humans. Gut 2003, 52(11):1537-1542.
31. Hellio Le Graverand M.P., Mazzuca S., Duryea J., Brett A. Radiographic grading and measurement of joint space width in osteoarthritis. Rheum Dis Clin North Am 2009, 35:485-502.